OncoMatch/Clinical Trials/NCT04043494
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Is NCT04043494 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for lymphoblastic lymphoma, childhood.
Treatment: Cyclophosphamide · Cytarabine · Dexamethasone · Daunorubicin · Doxorubicin · Ifosfamide · 6-Mercaptopurine · Methotrexate · PEG asparaginase · Prednisone · Prednisolone · Thioguanine · Vincristine · Vindesine — Primary objectives: * Randomization R1, all patients eligible: To examine, whether the cumulative incidence of relapses with involvement of the CNS (CNS relapse, pCICR) can be decreased by a modified induction therapy including dexamethasone (experimental arm) instead of prednisone (standard arm) * Randomization R2, only patients with high risk LBL eligible: to examine, whether the probability of event-free survival (pEFS) in these patients can be improved by receiving an intensified treatment arm versus a standard treatment arm (as used in the EURO-LB 02)
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Prior therapy
Cannot have received: steroid
Exception: pre-treatment with ≥ 1 mg/kg/d for more than two weeks during the last month before diagnosis
steroid pre-treatment with ≥ 1 mg/kg/d for more than two weeks during the last month before diagnosis
Cannot have received: cytostatic drugs
pre-treatment with cytostatic drugs
Lab requirements
Kidney function
severe renal impairment (creatinine clearance less than 20 ml/min) [excluded]
Liver function
severe hepatic impairment (bilirubin >3 times ULN, transaminases >10 times ULN) [excluded]
Cardiac function
myocardial insufficiency, severe arrhythmias [excluded]
severe renal impairment (creatinine clearance less than 20 ml/min); severe hepatic impairment (bilirubin >3 times ULN, transaminases >10 times ULN); myocardial insufficiency, severe arrhythmias
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify